Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond GLM: Inter-Subject Variability as a Complementary Approach to Detect Longitudinal Changes in Emotion Processing in Multiple Sclerosis.

Journal of imaging·2026
Same author

Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer's disease.

The Cochrane database of systematic reviews·2026
Same author

Serum miR-199a-3p and miR-103a-3p are possible biomarkers for the onset of multiple sclerosis.

Scientific reports·2026
Same author

Corrigendum to "Effect of hydration time on the microstructure of a porcine acellular dermal matrix for breast reconstruction: a pilot study" [J Plast Reconstr Aesthet Surg 106 (2025) 319-328].

Journal of plastic, reconstructive & aesthetic surgery : JPRAS·2026
Same author

Efficacy of traditional swallowing therapy plus neuromuscular electrostimulation in multiple sclerosis: A randomized controlled trial.

Multiple sclerosis and related disorders·2026
Same author

Recommendations for the use of off-label rituximab for the treatment of multiple sclerosis in low-resource settings.

Multiple sclerosis and related disorders·2025
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
Same journal

Non-pharmacological interventions for anxiety and depression in Parkinson's disease.

The Cochrane database of systematic reviews·2026
Same journal

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

The Cochrane database of systematic reviews·2026
Same journal

Preconception and first-trimester metformin for improving pregnancy outcomes in women with polycystic ovary syndrome.

The Cochrane database of systematic reviews·2026
See all related articles

Related Experiment Video

Updated: May 25, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Interferon beta for secondary progressive multiple sclerosis.

Loredana La Mantia1, Laura Vacchi, Carlo Di Pietrantonj

  • 1Unit of Neurology - Multiple Sclerosis Center, I.R.C.C.S. Santa Maria Nascente FondazioneDon Gnocchi, Via Capecelatro 66, Milano, 20148, Italy. lamantialore@gmail.com.

The Cochrane Database of Systematic Reviews
|January 20, 2012
PubMed
Summary
This summary is machine-generated.

Interferon (IFN) beta treatments do not prevent disability progression in Secondary Progressive Multiple Sclerosis (SPMS). However, IFNs significantly reduce relapses and short-term disability, showing an anti-inflammatory effect without halting established disease progression.

More Related Videos

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Related Experiment Videos

Last Updated: May 25, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Area of Science:

  • Neurology
  • Immunology
  • Clinical Trials

Background:

  • Recombinant interferons (IFNs) beta-1a and beta-1b are approved for Relapsing Remitting Multiple Sclerosis (RRMS).
  • A key question is whether IFNs can slow or reverse the progressive phase of MS.
  • This review focuses on the efficacy of IFNs in Secondary Progressive Multiple Sclerosis (SPMS).

Purpose of the Study:

  • To determine if interferon (IFN) beta treatment is more effective than placebo in reducing disability progression in SPMS patients.
  • To analyze the impact of IFNs on relapse rates and MRI-defined disease activity in SPMS.

Main Methods:

  • Systematic review of randomized, placebo-controlled trials (RCTs) of IFNs versus placebo in SPMS.
  • Searches included Cochrane MS Trials Register, reference lists, and regulatory agencies.
  • Data extraction and risk of bias assessment were performed independently by two reviewers.

Main Results:

  • Five RCTs involving 3122 patients (1829 IFN, 1293 placebo) were analyzed.
  • IFN beta did not reduce the risk of sustained disability progression at 6 months over three years.
  • A significant reduction in 3-month sustained progression and new relapses at three years was observed.
  • MRI data suggested a decrease in active brain lesions, despite no effect on clinical progression.
  • The safety profile of IFNs was consistent with known side effects in MS patients.

Conclusions:

  • Recombinant IFN beta does not prevent the development of permanent physical disability in SPMS.
  • IFN treatment significantly reduces the risk of relapses and short-term disability.
  • The anti-inflammatory effects of IFNs do not halt established disease progression in SPMS.